Literature DB >> 12127155

L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.

Christian Winkler1, Deniz Kirik, Anders Björklund, M Angela Cenci.   

Abstract

In order to assess the role of striatal dopamine (DA) afferents in L-DOPA-induced dyskinesia, we have studied a large series of rats sustaining 2, 3, or 4 unilateral injections of 6-hydroxydopamine (6-OHDA) in the lateral striatum. This type of lesion produced a dose-dependent depletion of DA fibers in the caudate-putamen, which was most pronounced in the lateral aspects of this structure. An additional group of rats was injected with 6-OHDA in the medial forebrain bundle to obtain complete DA denervation on one side of the brain. During a course of chronic L-DOPA treatment, rats with intrastriatal 6-OHDA lesions developed abnormal involuntary movements (AIMs), which mapped onto striatal domains exhibiting at least approximately 90% denervation, as judged by DA transporter autoradiography. The denervated areas showed local upregulation of preproenkephalin and prodynorphin mRNA, and FosB-like immunoreactivity, which were highly correlated with the rats' AIM scores. When compared to completely DA-denervated animals, the rats with intrastriatal 6-OHDA lesions showed an overall lower incidence, lower severity and different topographic distribution of AIMs. The involvement of proximal limb and axial muscles in the abnormal movements was proportional to the spreading of the lesion from lateral towards medial aspects of the caudate-putamen. Locomotive AIMs were only seen in rats with complete lesions, but not in any of the animals with intrastriatal 6-OHDA (which showed > 5% DA fiber sparing in the medial striatum). Intrastriatally 6-OHDA-lesioned rats had a larger therapeutic window for L-DOPA than did rats with complete bundle lesions, since they exhibited an overall lower predisposition to dyskinesia but a similar degree of drug-induced motor improvement in a test of forelimb stepping. Our results are the first to demonstrate that selective and partial DA denervation in the sensorimotor part of the striatum can confer cellular and behavioral supersensitivity to L-DOPA, and that the phenomenology of L-DOPA-induced rat AIMs can be accounted for by the topography of DA denervation within the caudate-putamen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12127155     DOI: 10.1006/nbdi.2002.0499

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  98 in total

1.  Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.

Authors:  K Elisabet Ohlin; Irene Sebastianutto; Chris E Adkins; Cornelia Lundblad; Paul R Lockman; M Angela Cenci
Journal:  Neuroimage       Date:  2012-03-03       Impact factor: 6.556

Review 2.  The interhemispheric connections of the striatum: Implications for Parkinson's disease and drug-induced dyskinesias.

Authors:  Christopher A Lieu; Thyagarajan Subramanian
Journal:  Brain Res Bull       Date:  2011-09-24       Impact factor: 4.077

3.  The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.

Authors:  Manfred Gerlach; Paul Halley; Peter Riederer; Maarten van den Buuse
Journal:  J Neural Transm (Vienna)       Date:  2012-05-17       Impact factor: 3.575

4.  Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.

Authors:  Nathalie Turle-Lorenzo; Nathalie Breysse; Christelle Baunez; Marianne Amalric
Journal:  Psychopharmacology (Berl)       Date:  2005-02-22       Impact factor: 4.530

5.  Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.

Authors:  Jordi Bové; Jordi Serrats; Guadalupe Mengod; Roser Cortés; Eduardo Tolosa; Concepció Marin
Journal:  Exp Brain Res       Date:  2005-06-21       Impact factor: 1.972

6.  The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Christopher Bishop; S Paul Berger; Melanie A Paquette
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

7.  Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice.

Authors:  Lisa Won; Yunmin Ding; Pardeep Singh; Un Jung Kang
Journal:  J Neurosci       Date:  2014-02-19       Impact factor: 6.167

8.  Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

Authors:  A A Martinez; M G Morgese; A Pisanu; T Macheda; M A Paquette; A Seillier; T Cassano; A R Carta; A Giuffrida
Journal:  Neurobiol Dis       Date:  2014-12-05       Impact factor: 5.996

9.  Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.

Authors:  Romulo Fuentes; Per Petersson; William B Siesser; Marc G Caron; Miguel A L Nicolelis
Journal:  Science       Date:  2009-03-20       Impact factor: 47.728

10.  The basal ganglia and cerebellum interact in the expression of dystonic movement.

Authors:  Vladimir K Neychev; Xueliang Fan; V I Mitev; Ellen J Hess; H A Jinnah
Journal:  Brain       Date:  2008-07-26       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.